Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;.

Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics. 2018;38:200–17.

Article  PubMed  Google Scholar 

Combes AD, Palma CA, Calopedos R, et al. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. Diagnostics (basel). 2022;12.

Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol. 2004;19:715–8.

CAS  PubMed  Google Scholar 

Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13:226–35.

Article  CAS  PubMed  Google Scholar 

Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466–86.

Article  PubMed  PubMed Central  Google Scholar 

Sheikhbahaei S, Werner RA, Solnes LB, et al. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Semin Nucl Med. 2019;49:255–70.

Article  PubMed  Google Scholar 

Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55–62.

Article  CAS  PubMed  Google Scholar 

Mease RC, Dusich CL, Foss CA, et al. N‑[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin. Cancer Res. 2008;14:3036–43.

CAS  Google Scholar 

Szabo Z, Mena E, Rowe SP, et al. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015;17:565–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giesel FL, Will L, Lawal I, et al. Intraindividual Comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med. 2018;59:1076–80.

Article  CAS  PubMed  Google Scholar 

Rauscher I, Langbein, T., Elshenawy KH, S. , D’Alessandria C, Fütterer CW, W. A. EIber, M. Evaluation of qualitative and quantitative PET parameters in primary prostate cancer patients: double-match comparison of 18F-flotufolastat- and 68Ga-PSMA-11-PET. J Nucl Med. 2024;65.

Robu S, Schottelius M, Eiber M, et al. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. J Nucl Med. 2017;58:235–42.

Article  CAS  PubMed  Google Scholar 

Maurer T, Robu S, Schottelius M, et al. (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2019;75:659–66.

Article  PubMed  Google Scholar 

Gandaglia G, Mazzone E, Stabile A, et al. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. Eur Urol. 2022;82:411–8.

Article  PubMed  Google Scholar 

Liu H, Zhang X, Zhang J, et al. Comparison of (64)Cu-DOTA-PSMA-3Q and (64)Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging. Eur J Nucl Med Mol Imaging. 2025.

Grubmuller B, Baum RP, Capasso E, et al. (64)Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. Cancer Biother Radiopharm. 2016;31:277–86.

PubMed  Google Scholar 

Jeitner TM, Babich JW, Kelly JM. Advances in PSMA theranostics. Transl Oncol. 2022;22:101450.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krasnovskaya OO, Abramchuck D, Erofeev A, et al. Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals. Int J Mol Sci. 2023; 24.

Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117–36.

Article  PubMed  Google Scholar 

Luckerath K, Wei L, Fendler WP, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018;8:96.

Article  PubMed  PubMed Central  Google Scholar 

Rowe SP, Gorin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. Ann Nucl Med. 2015;29:877–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tolkach Y, Gevensleben H, Bundschuh R, et al. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat. 2018;169:447–55.

Article  CAS  PubMed  Google Scholar 

Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. Clin Nucl Med. 2016;41:414–6.

Article  PubMed  Google Scholar